Alexion Looks To Broaden Complement Inhibitor Market With Next-Generation Ultomiris

 
• By John Davis

Positive late-stage clinical results involving Ultomiris in a second potential indication suggest Alexion is on the right track to develop new ultra-rare disease therapies with significant commercial potential.  

Stepping stones
Alexion is taking steps to add further indications to its next-generation complement inhibitor • Source: Shutterstock

More from Blood and Clotting

More from Therapy Areas